Bank of Montreal Can Buys 25,002 Shares of Solventum Co. (NYSE:SOLV)

Bank of Montreal Can grew its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 15.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 182,748 shares of the company's stock after purchasing an additional 25,002 shares during the quarter. Bank of Montreal Can owned approximately 0.11% of Solventum worth $12,348,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Deseret Mutual Benefit Administrators acquired a new stake in Solventum in the second quarter valued at $25,000. Hollencrest Capital Management bought a new position in shares of Solventum during the second quarter worth about $25,000. Richard W. Paul & Associates LLC acquired a new position in shares of Solventum in the second quarter worth approximately $26,000. Family Firm Inc. acquired a new position in shares of Solventum in the second quarter worth approximately $26,000. Finally, Copeland Capital Management LLC bought a new stake in Solventum in the third quarter valued at approximately $26,000.

Analyst Ratings Changes

Several research firms have issued reports on SOLV. Piper Sandler raised their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a report on Friday, November 8th. Stifel Nicolaus assumed coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price on the stock. Wells Fargo & Company decreased their price target on Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a report on Friday, August 9th. BTIG Research assumed coverage on Solventum in a research note on Thursday, September 5th. They issued a "neutral" rating on the stock. Finally, Morgan Stanley raised their target price on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $68.00.

Solventum Trading Up 0.6 %

Shares of NYSE SOLV traded up $0.44 during midday trading on Monday, hitting $71.95. 984,368 shares of the stock traded hands, compared to its average volume of 1,685,013. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The business has a 50 day moving average price of $70.55 and a two-hundred day moving average price of $62.58.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.